PARP1 and malignant colon neoplasm: Recently, we have reported that low levels of CCDC6 associates with an impariment of Homologous Recombination (HR) mechanisms affecting cells behaviour and cells sensitivity to PARP inhibitors treatment in lung and colon cancer models [16, 22].